CA-TECHNICOLOR-PRECISION
16.8.2021 15:02:14 CEST | Business Wire | Press release
Technicolor Precision BioDevices (TPB), a member of the creative technology leader Technicolor (Euronext Paris: TCH, OTCQX: TCLRY), announces a collaboration with Scope Fluidics to manufacture cartridges for their BacterOMIC system.
Scope Fluidics develops innovative projects in diagnostics and health care. Established in 2010, they develop solutions with a high market potential across two core divisions: Curiosity Diagnostics and Bacteromic.
Technicolor Precision BioDevices will provide small-scale production of the BacterOMIC cartridges. The BacterOMIC system provides quantitative assessment of bacterial susceptibility to a wide range of antibiotics in a single test and is currently being tested in three independent laboratories. The cartridges will be manufactured in TPB’s Warsaw, Poland facility initially under a one-year agreement, featuring a dedicated manufacturing line for pilot and scale production, and further process optimization for reducing the cost of the consumable cartridges.
David Holliday, President of Technicolor HES commented: “Technicolor is a world leading provider of precision manufacturing and related supply chain services with a long legacy of serving media and entertainment customers, and in recent years we have been an expanding presence in the medical diagnostic and life science markets under the Technicolor Precision BioDevices tradename. Technicolor will be supporting manufacturing of the BacterOMIC cartridges from its existing production facility in Piaseczno, a suburb of Warsaw, Poland. We’re very pleased to be collaborating with Scope Fluidics Group for this pilot manufacturing phase.”
“This is an important factor in building the market value of both the BacterOMIC system and the company itself. During the term of the agreement, we also intend to negotiate the terms of our potential cooperation in large-scale cartridge manufacturing. We believe that in this way we will better prepare Bacteromic for the market,” said Marcin Izydorzak, Member of the Board of Scope Fluidics S.A.
California-based Technicolor Precision BioDevices is a certified ISO 13485 contract manufacturer of custom injection molded microfluidic components and consumables for the medical devices and life sciences industries. With facilities worldwide, it is capable of providing rapid product realization – leveraging TPB’s Design for Manufacturability prototyping expertise to quickly transitioning into high volume manufacturing, specialist packaging and shipping.
Learn more about TPB at http://microfluidics.technicolor.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210816005331/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Empire State Building Presents First-Ever Children’s Birthday Party Package for Celebrations at the Iconic Observatory Experience23.2.2026 15:13:00 CET | Press release
Express Access, Party Favors, and Private Room with Decorations and Ghirardelli Ice Cream Sundaes Parents who have looked for the best birthday party idea for their children have had their wish fulfilled. Today, the Empire State Building (ESB) announced the debut of its first-ever ESB Birthday Party Package for kids at the international icon’s Observatory as part of year-long 95th anniversary celebrations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223161708/en/ The Empire State Building Presents First-Ever Children’s Birthday Party Package for Celebrations at the Iconic Observatory Experience “From Lego playtime to Percy Jackson readers, children love the Empire State Building and now parents can give an unmatched experience to their children and their friends,” said Anthony E. Malkin, chairman and CEO of Empire State Realty Trust. “This birthday party package tops them all with an escorted visit through our world-fa
Xsolla Co-Sponsors Gamescom Dev Leadership Summit in Lisbon, Bringing Together Gaming Industry Leaders to Shape the Future of Game Development23.2.2026 15:00:00 CET | Press release
Platform Supporting 1,500+ Game Developers Across 200+ Geographies to Host Networking Dinner and Co-Moderate Strategic Roundtable at Premier European Gaming Executive Summit Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced its co-sponsorship of the Gamescom Dev Leadership Summit Lisbon, taking place February 24-26 at SUD Lisboa in Portugal. The event brings together gaming industry executives, studio founders, and business leaders to explore opportunities and innovations shaping the future of game development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223253705/en/ Graphic: Xsolla As part of its sponsorship, Xsolla will host the summit's Wednesday evening networking dinner and co-moderate a strategic roundtable session focused on business models and sustainable growth in the gaming industry. "We're seeing incredible innovation from studios acro
CoolMPS™ 600: Accurate and Affordable Long MPS/NGS Reads on a Mid-Throughput Platform23.2.2026 15:00:00 CET | Press release
Swiss Rockets AG announces that its CoolMPS 600 mid-throughput sequencer with advanced chemistry and novel MPS/NGS read length will become available in Q2 2026. Enabled by its exclusive license of CoolMPS technology, Swiss Rockets AG is developing its first sequencer, CoolMPS 600, through contract R&D with Complete Genomics since August 2025. The platform is utilizing the company’s proprietary antibody-based CoolMPS™ chemistry combined with DNBSEQ™, a real PCR-free DNA nanoarray technology. Separately, Swiss Rockets AG announced that it has entered into a definitive agreement to acquire 100% ownership of Complete Genomics. CoolMPS 600 enables cost-effective extended single-end sequencing to 600 bases (SE600) while maintaining high base accuracy. The system is designed to support advanced whole-genome sequencing (WGS) with improved mapping accuracy across complex genomic regions, including better detection of structural variants. It also enables full length transcriptomes and more infor
Angelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreement to Discover and Advance Novel Therapeutics for Genetic Epilepsies23.2.2026 14:08:00 CET | Press release
Angelini Pharma secures exclusive global license rights to future identified drug targets Quiver receives undisclosed advance payment and is eligible for future milestone-dependent payments and royalties Collaboration further expands Angelini Pharma’s focus on brain health, building on its deep therapeutic expertise and drug development experience Angelini Pharma, part of the privately owned Angelini Industries, and Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for the treatment of central nervous system (CNS) disorders, announced today that they have entered into a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies. The collaboration brings together Quiver’s unique drug discovery capabilities, data assets, and AI models with Angelini Pharma’s established expertise in brain health and epilepsy drug development. This press release features multimedia. View the full release here: https://www.busine
Armis Achieves U.S. Department of Defense Impact Level 5 Authorization23.2.2026 14:00:00 CET | Press release
DoD customers can now leverage Armis Centrix™ with enhanced security controls and connectivity Armis, the cyber exposure management & security company, today announced that it has achieved authorization from the U.S. DoD’s Defense Information Systems Agency (DISA) to operate at an Impact Level 5 (IL5). This means that Armis has met strict requirements to manage and secure the DoD’s critical infrastructure, including Controlled Unclassified Information (CUI) systems. “We are committed to helping Federal agencies like the Department of Defense address their toughest cybersecurity challenges,” said Alex Mosher, President and CRO at Armis. “Achieving DISA IL5 authorization is an important milestone for Armis as we continue to support DoD customers in safeguarding critical systems, sensitive data and national security infrastructure from evolving cyber threats.” Armis empowers Federal agencies to build and optimize comprehensive cybersecurity programs with Armis Centrix™, the FedRAMP and DI
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom